R and D-Biopharmaceuticals GmbH
R&D-Biopharmaceuticals GmbH (R&D-Biopharmaceuticals) is a privately held development-stage biotechnology company. It is principally engaged in the pre-clinical and clinical development of small molecules deriving from natural products targeting diseases with unmet medical need. R&D-Biopharmaceuticals owns exclusive access to the natural product class of the Tubulysins and to next generation epothilones, a highly promising new drug class helpful in treating cancer. In addition, the company has plans to in-license later stage products to complement its pipeline. R&D-Biopharmaceuticals is headquartered in Planegg, Germany.